Krystal Biotech (NASDAQ:KRYS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Tuesday. The firm currently has a $28.00 price objective on the stock. Zacks Investment Research‘s target price suggests a potential upside of 6.99% from the company’s previous close.
According to Zacks, “Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States. “
Several other research analysts have also commented on the company. Cantor Fitzgerald reiterated a “buy” rating and set a $35.00 price target on shares of Krystal Biotech in a report on Monday, October 15th. HC Wainwright boosted their price objective on shares of Krystal Biotech from $32.00 to $35.50 and gave the company a “buy” rating in a report on Monday, October 15th. Cowen initiated coverage on shares of Krystal Biotech in a report on Wednesday, December 12th. They issued an “outperform” rating on the stock. ValuEngine upgraded shares of Krystal Biotech from a “hold” rating to a “buy” rating in a report on Friday, September 21st. Finally, William Blair restated a “buy” rating on shares of Krystal Biotech in a report on Monday, November 5th. Eight equities research analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and an average price target of $33.40.
Shares of KRYS stock opened at $26.17 on Tuesday. Krystal Biotech has a fifty-two week low of $8.61 and a fifty-two week high of $28.75. The firm has a market capitalization of $366.06 million, a price-to-earnings ratio of -17.68 and a beta of 0.62.
Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, November 5th. The company reported ($0.26) EPS for the quarter, hitting the consensus estimate of ($0.26). As a group, equities research analysts forecast that Krystal Biotech will post -0.95 earnings per share for the current fiscal year.
In related news, insider Krish S. Krishnan acquired 25,000 shares of Krystal Biotech stock in a transaction that occurred on Thursday, October 18th. The shares were purchased at an average cost of $20.00 per share, for a total transaction of $500,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 45.80% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc raised its holdings in Krystal Biotech by 13.1% in the 3rd quarter. Vanguard Group Inc now owns 173,478 shares of the company’s stock valued at $3,050,000 after buying an additional 20,100 shares during the period. Vanguard Group Inc. raised its holdings in Krystal Biotech by 13.1% in the 3rd quarter. Vanguard Group Inc. now owns 173,478 shares of the company’s stock valued at $3,050,000 after buying an additional 20,100 shares during the period. Renaissance Technologies LLC purchased a new stake in Krystal Biotech in the 3rd quarter valued at about $891,000. S Squared Technology LLC purchased a new stake in Krystal Biotech in the 3rd quarter valued at about $948,000. Finally, JPMorgan Chase & Co. grew its position in Krystal Biotech by 69.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 36,133 shares of the company’s stock valued at $635,000 after acquiring an additional 14,755 shares in the last quarter. Hedge funds and other institutional investors own 18.83% of the company’s stock.
About Krystal Biotech
Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease.
Recommended Story: How to Invest in Growth Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.